Inhibikase Therapeutics (Nasdaq: IKT) granted non-qualified stock options for up to 981,243 shares to seven newly hired non-executive employees under its 2026 Inducement Equity Plan, effective June 30, 2026. Options have a $2.03 exercise price, ten-year term, and structured four-year vesting schedule.
Loading...
Loading translation...
Positive
Inducement options for 981,243 shares to recruit seven new employees
Exercise price set at $2.03, equal to closing market price on grant date
Negative
Potential future dilution from options covering 981,243 additional shares
News Market Reaction – IKT
-0.50%
-0.50%Session close to close
In the Jul 6 session, IKT declined 0.50%, reflecting a mild negative market reaction.
The company granted 981,243 at-market stock options to seven new employees under its 2026 inducement...
Analysis
The company granted 981,243 at-market stock options to seven new employees under its 2026 inducement plan, adding modest equity compensation. With an effective S-3 shelf and notable short positioning, future financing or sentiment shifts remain key watchpoints.
Key Figures
Inducement options granted:981,243 sharesNumber of new employees:7 employeesExercise price:$2.03 per share+3 more
"the Company granted non-qualified stock options to purchase up to an aggregate"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
inducement planfinancial
"employees under the Company’s 2026 Inducement Equity Plan (the “Inducement Plan”)"
An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.
nasdaq listing rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
WILMINGTON, Del., July 02, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to purchase up to an aggregate of 981,243 shares of the Company’s common stock to seven newly-hired non-executive employees under the Company’s 2026 Inducement Equity Plan (the “Inducement Plan”), effective as of June 30, 2026 (the “Effective Date”).The inducement grants were previously approved by the Compensation Committee of the Company’s Board of Directors, as a material inducement to the new employees’ entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $2.03 per share, which is equal to the closing price of the Company’s common stock on the Effective Date.The options have a ten year term, with 25% vesting on the first anniversary of the Effective Date and the remaining 75% vesting in 36 equal monthly installments thereafter. The options are subject to the terms and conditions of the Inducement Plan approved by the Company’s Board of Directors in March 2026 and the terms and conditions of award agreements covering the grants.
About Inhibikase Therapeutics
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (“PAH”), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as “c-Kit” has been implicated. Our lead product candidate is IKT-001, a prodrug of imatinib mesylate (“imatinib”), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety profile with the first reported use of imatinib in PAH occurring in 2005. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans. Our single pivotal Phase 3 clinical study in PAH in approximately 180 sites around the world, named IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH), is actively enrolling patients.
Contacts: Investor Relations: Michael Moyer LifeSci Advisors mmoyer@lifesciadvisors.com
FAQ
What inducement stock option grants did Inhibikase Therapeutics (NASDAQ: IKT) announce on July 2, 2026?
Inhibikase announced non-qualified stock options for up to 981,243 shares granted to seven new non-executive employees. According to Inhibikase, these options were issued under the 2026 Inducement Equity Plan as a material inducement for employment under Nasdaq Listing Rule 5635(c)(4).
What is the exercise price of the new Inhibikase (IKT) inducement stock options?
The inducement stock options have an exercise price of $2.03 per share. According to Inhibikase, this price equals the closing price of its common stock on June 30, 2026, the effective date of the grants under the 2026 Inducement Equity Plan.
What are the vesting terms for Inhibikase Therapeutics’ June 30, 2026 inducement options (IKT)?
The options vest over four years with a ten-year term. According to Inhibikase, 25% vests on the first anniversary of June 30, 2026, and the remaining 75% vests in 36 equal monthly installments thereafter, subject to plan and award conditions.
How could the new Inhibikase (IKT) inducement stock options affect the company’s share count?
If fully exercised, the options would add up to 981,243 shares to the share count. According to Inhibikase, these non-qualified options were granted to seven newly hired non-executive employees under the 2026 Inducement Equity Plan.
Under which plan were the Inhibikase Therapeutics (IKT) inducement options granted and when was it approved?
The options were granted under the 2026 Inducement Equity Plan. According to Inhibikase, the Board of Directors approved this plan in March 2026, and the Compensation Committee approved the inducement grants as a material inducement to new employees.
Why did Inhibikase Therapeutics (IKT) use Nasdaq Listing Rule 5635(c)(4) for these stock option grants?
Inhibikase used Nasdaq Listing Rule 5635(c)(4) to issue inducement grants as a material incentive for new hires. According to Inhibikase, the rule permits equity awards to new employees outside stockholder-approved plans when used as an employment inducement.
